2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 15:28, 21 November 2023
, 21 November 2023no edit summary
No edit summary |
|||
| Line 127: | Line 127: | ||
* '''Safety''': basically safe under the existing intervention dose and time | * '''Safety''': basically safe under the existing intervention dose and time | ||
* '''Sleep quality''': no significant improvement^35,118 | * '''Sleep quality''': no significant improvement^35,118 | ||
* '''Physical activity''': prevented aging-related muscle dysfunctions and improving physical performance^118, | * '''Physical activity''': prevented aging-related muscle dysfunctions and improving physical performance^118,{{pmid|35927255}},145,146 | ||
* '''Eye''': no significant improvement^35 | * '''Eye''': no significant improvement^35 | ||
* '''Ear''': improved the right auditory ability of old men | * '''Ear''': improved the right auditory ability of old men{{pmid|35927255}} | ||
* '''Cognition''': no significant improvement | * '''Cognition''': no significant improvement{{pmid|35927255}} | ||
* '''Diabetes''': increased muscle insulin sensitivity, insulin signaling, and remodeling in prediabetic women^36 | * '''Diabetes''': increased muscle insulin sensitivity, insulin signaling, and remodeling in prediabetic women^36 | ||
* '''Telomere''': increased telomere length^147 | * '''Telomere''': increased telomere length^147 | ||